Subcutaneous furosemide in heart failure: a systematic review
European Heart Journal - Cardiovascular Pharmacotherapy · 2025
DOI: 10.1093/ehjcvp/pvae083 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2025. Verfasst von Joanna Osmanska und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow 126 University …. Hauptthemen laut MEDLINE: Furosemide, Heart Failure, Sodium Potassium Chloride Symporter Inhibitors, Diuresis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation Centre of Research Excellence.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background and aim Intravenous loop diuretics are the primary treatment for congestion in patients with decompensated heart failure (HF). Furosemide is the most commonly used loop diuretic and is licensed for administration either orally, intramuscularly or intravenously but not subcutaneously. Recently developed, pH-neutral, concentrated, and ‘skin-friendly’ preparations of furosemide have been developed which allow subcutaneous administration. In this systematic review, we summarize and critically appraise the current evidence for subcutaneous furosemide in patients with HF. Methods and results The electronic databases MEDLINE, EMBASE, the Cochrane Library, and ClinicalTrials.gov registry were searched up to 30 September 2024. Of the 17 studies identified, 5 were randomized controlled trials (RCTs), 2 were non-randomized controlled studies, 3 were prospective observational cohort studies, and 7 were retrospective observational studies. All RCTs utilized novel pH-neutral, subcutaneous preparations of furosemide. Bioavailability of novel subcutaneous preparations were similar to intravenous furosemide 10 mg/mL: 99.7% for an 8 mg/mL preparation and 112% for a 30 mg/mL preparation. Natriuresis and diuresis were also similar with novel subcutaneous and conventional intravenous furosemide. Adverse events related to novel preparations included infusion site pain or discomfort, localized skin erythema and minimal swelling. All studies of subcutaneous conventional furosemide were non-randomized with very few data regarding bioavailability or diuretic and natriuretic effect. Subcutaneous conventional furosemide was associated with substantial skin irritation (affecting 3–23% of patients), and skin infections requiring treatment with antibiotics (3–17%). Conclusion Novel, pH-neutral preparations of subcutaneous furosemide achieved similar diuresis, natriuresis, and bioavailability to intravenous furosemide, and were well tolerated. Novel preparations may be a treatment option for patients with HF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cardiovascular and Metabolic Health, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow 126 University Place, Glasgow G12 8TA, UK.
ORCID-Profile: Joanna Osmanska, Mark C Petrie, Kieran F Docherty, Matthew M Y Lee, John J V McMurray, Ross T Campbell
Förderung
- British Heart Foundation Centre of Research Excellence
Zitieren
APA
Osmanska, J., Petrie, M. C., Docherty, K. F., Lee, M. M. Y., McMurray, J. J. V., & Campbell, R. T. (2025). Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae083
Vancouver
Osmanska J, Petrie MC, Docherty KF, Lee MMY, McMurray JJV, Campbell RT. Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal - Cardiovascular Pharmacotherapy. 2025. doi:10.1093/ehjcvp/pvae083
BibTeX
@article{Osmanska2025,
author = {Osmanska, Joanna and Petrie, Mark C and Docherty, Kieran F and Lee, Matthew M Y and McMurray, John J V and Campbell, Ross T},
title = {Subcutaneous furosemide in heart failure: a systematic review},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2025},
doi = {10.1093/ehjcvp/pvae083}
}
EUVIMED